Related Experiment Videos
MDM2 sensitizes a human ovarian cancer cell line
1Department of Gynecology and Obstetrics, General Hospital of TianJin Medical University, Tianjin, China.
Objectives:
The purpose of this study was to determine whether overexpression of MDM2 could sensitize the ovarian cancer cell line A2780.
Methods:
The wild-type p53-expressing cell line A2780 was stably transfected with pCMV-MDM2 (A2780-MDM2) or pCMV (A2780-V) as control. MTT assay and clonogenic survival assay were used to measure the cisplatin sensitivity. FACS and host cell (CAT) reactivation assay were used to estimate the change of cell cycle and ability of repairing cisplatin-induced DNA damage.
Results:
Parental A2780 and A2780-V had similar cisplatin sensitivities, whereas A2780-MDM2 was two- to threefold more sensitive to cisplatin. Repair of cisplatin-induced DNA damage was reduced in A2780 cells overexpressing MDM2, compared to A2780 cells in which wild-type p53 function was intact. After cisplatin treatment, A2780-MDM2 cells showed a pronounced S-phase arrest; however, A2780 cells with intact wild-type p53 arrested primarily in G2/M phase.
Conclusions:
MDM2 overexpression can increase cisplatin cytotoxicity in A2780, with loss of G1/S checkpoint control and decreased cisplatin-DNA adduct repair. This suggests that ovarian cancers that overexpress MDM2 may be amenable to treatment with platinum compounds.
Insights
Overexpression of MDM2 enhances cisplatin sensitivity in ovarian cancer cells by impairing DNA repair and altering cell cycle arrest. This suggests MDM2-overexpressing ovarian cancers may respond well to platinum-based chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- MDM2 is a key regulator of p53 tumor suppressor.
- Dysregulation of MDM2 is implicated in various cancers.
- Understanding MDM2's role in chemoresistance is crucial for ovarian cancer treatment.
Purpose of the Study:
- To investigate the effect of MDM2 overexpression on cisplatin sensitivity in the A2780 ovarian cancer cell line.
- To determine if MDM2 overexpression influences DNA damage repair and cell cycle progression following cisplatin treatment.
Main Methods:
- Stable transfection of A2780 cells with MDM2 or control vector.
- Assessment of cisplatin sensitivity using MTT and clonogenic survival assays.
- Analysis of cell cycle distribution (FACS) and DNA repair capacity (host cell reactivation assay).
Main Results:
- MDM2-overexpressing A2780 cells exhibited 2- to 3-fold increased sensitivity to cisplatin.
- Cisplatin-induced DNA damage repair was reduced in cells overexpressing MDM2.
- MDM2 overexpression led to S-phase arrest, while wild-type p53 cells showed G2/M arrest after cisplatin treatment.
Conclusions:
- MDM2 overexpression increases cisplatin cytotoxicity in A2780 cells.
- This sensitization is associated with impaired G1/S checkpoint control and reduced DNA repair.
- Ovarian cancers with high MDM2 expression may benefit from platinum compound therapy.